Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 30, 2025Hepatology CommunicationsOpen Access

High biochemical remission rates in patients with primary biliary cholangitis treated with “triple” anticholestatic therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

GCGuilherme Grossi Lopes CançadoBCBo ChenMCMadeline Cameron

Discussion

Loading...

Member takes

Overview

Observational analysis shows triple therapy improves ALP levels in patients with primary biliary cholangitis, suggesting enhanced treatment effectiveness.

Key Points

  • Triple anticholestatic therapy achieved a median 33.3% reduction in alkaline phosphatase at 6 months, with 30% normalizing their ALP.
  • Among patients on triple therapy, 82% had obeticholic acid as the first add-on, and 92% received bezafibrate during treatment.
  • Multivariate analysis indicated older age at diagnosis significantly influenced the normalization of alkaline phosphatase levels.
  • The findings underscore the effectiveness of FXR-PPAR-UDCA triple therapy in improving biochemical outcomes in primary biliary cholangitis.

Cite This Study

Cançado et al. (2025) studied this question.

synapsesocial.com/papers/68dc1e308a7d58c25ebb15a8https://doi.org/10.1097/hc9.0000000000000798
View Full Paper
Ask AI
Bookmark
Share